

## Catalog # 10-1315 PX-866

CAS# 502632-66-8 Lot # X104093

Inhibits PI-3 Kinase with selectivity for p110 $\alpha$  (IC<sub>50</sub>=0.1 nM). Counteracts hypoxia related down regulation of E7 expression in HPV-positive cancer cells.<sup>2</sup> Displays antitumor activity. Irreversible. Cell permeable.

- 1) Ihle et al. (2004), Molecular pharmacology and antitumor activity of PK-866, a novel inhibitor of phosphoinositide-3-kinase signaling; Mol. Cancer Ther., **3** 763
- 2) Bossler et al. (2019), Repression of Human Papilloma Virus Oncogene Expression Under Hypoxia is Mediated by PI3K/mTORC2/AKT Signaling; mBio, **10** e02323

## **PHYSICAL DATA**

 $\begin{array}{lll} \mbox{Molecular Weight:} & 525.60 \\ \mbox{Molecular Formula:} & C_{29}\mbox{H}_{35}\mbox{NO}_{8} \\ \mbox{Purity:} & 98\% \mbox{ by TLC} \end{array}$ 

NMR: (Conforms)

Solubility: DMSO (up to 25 mg/ml)

Physical Description: Orange solid

Storage and Stability: Store as supplied desiccated at -20°C for up to 2 years from the date of purchase. Solutions in

DMSO may be stored at -20°C for up to 2 months.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.